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Abstract
Background: ‘‘Imaging genetics’’ studies have shown that brain function by neuroimaging is a sensitive intermediate
phenotype that bridges the gap between genes and psychiatric conditions. Although the evidence of association between
functional val108/158met polymorphism of the catechol-O-methyltransferase gene (COMT) and increasing risk for
developing schizophrenia from genetic association studies remains to be elucidated, one of the most topical findings from
imaging genetics studies is the association between COMT genotype and prefrontal function in schizophrenia. The next
important step in the translational approach is to establish a useful neuroimaging tool in clinical settings that is sensitive to
COMT variation, so that the clinician could use the index to predict clinical response such as improvement in cognitive
dysfunction by medication. Here, we investigated spatiotemporal characteristics of the association between prefrontal
hemodynamic activation and the COMT genotype using a noninvasive neuroimaging technique, near-infrared spectroscopy
(NIRS).
Methodology/Principal Findings: Study participants included 45 patients with schizophrenia and 60 healthy controls
matched for age and gender. Signals that are assumed to reflect regional cerebral blood volume were monitored over
prefrontal regions from 52-channel NIRS and compared between two COMT genotype subgroups (Met carriers and Val/Val
individuals) matched for age, gender, premorbid IQ, and task performance. The [oxy-Hb] increase in the Met carriers during
the verbal fluency task was significantly greater than that in the Val/Val individuals in the frontopolar prefrontal cortex of
patients with schizophrenia, although neither medication nor clinical symptoms differed significantly between the two
subgroups. These differences were not found to be significant in healthy controls.
Conclusions/Significance: These data suggest that the prefrontal NIRS signals can noninvasively detect the impact of COMT
variation in patients with schizophrenia. NIRS may be a promising candidate translational approach in psychiatric
neuroimaging.
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Introduction
Schizophrenia is a complex psychiatric disease that is speculated
to result from multiple genetic and environmental factors. Due to
familial aggregation and high heritability, the involvement of
genetic factors in the onset of schizophrenia is considered to be
relatively large [1].
The gene for catechol-O-methyltransferase (COMT) that
metabolizes released dopamine is one of the susceptibility genes
located in chromosome 22q11.2 and has been repeatedly reported
to be involved in schizophrenia [2–5]. Many association studies
have indicated the involvement of a functional polymorphism
(Met108/158Val) (rs4680) with the slight increase in risk for
schizophrenia [6,7]. However, other studies have reported no
PLoS ONE | www.plosone.org 1 May 2009 | Volume 4 | Issue 5 | e5495association [8,9] and there are several other putatively functional
single nucleotide polymorphisms (SNPs) that have been implicated
[10,11]. Thus, the association studies are yet to converge on a
consistent finding.
Meanwhile, in humans, there is a COMT genotype (Met108/
158Val) where a fourfold reduction of COMT enzyme activity is
derived from the substitution of a valine (Val) by a methionine
(Met) [12]. Moreover, the activity of the COMT enzyme is
assumed to modulate dopamine levels in the prefrontal cortex
(PFC) [13,14]. A few reports suggested the inverted-U-shape
phenomenon in the relationship between dopamine level and
brain function. The phenomenon is based on the hypothesis that
there would be an optimal prefrontal level of dopamine for
efficient physiological signaling and optimal performance, and that
PFC function was impaired when dopaminergic nervous trans-
mission was either too far above or below normal levels [15–17].
Some studies indicated that the COMT Val/Met genotype has an
effect on the response to antipsychotic drugs, because dopamine
release in the PFC is enhanced by antipsychotic medication
[14,18]. Other studies suggested that a subpopulation of patients
with the COMT Met genotype might respond more favorably to
antipsychotic treatment [19,20]. Also, these studies showed that
functional MRI changes associated with good cognitive response
to antipsychotic drugs were predicted on the basis of the COMT
genotype. It would be ideal for clinical application and
translational approach if neuroimaging techniques could be used
to determine the intermediate phenotype to help predict such
effects before starting the treatment.
From the perspective of clinical application and translational
approach, the use of a less psychologically and physically
demanding neuroimaging method is necessary. Conducting
neuroimaging that requires less restraint on movement and less
time is better for patients, particularly psychiatric patients.
Multichannel near-infrared spectroscopy (NIRS), a relatively
new functional neuroimaging technology, is one of the potent
candidates that is restraint-free, easy-to-use, portable and
noninvasive. Furthermore, the NIRS equipment is relatively
inexpensive and with almost no running cost except for the
electricity charges during use. Some neuroimaging techniques
have limitations in that the measurement makes the subjects
uncomfortable in an unnatural setting, e.g., lying in a supine
position in a narrow gantry and fixing the head during the entire
examination. In contrast, NIRS measurement under natural
conditions, in a sitting position in a well-lit room, may overcome
these limitations. We have sought to establish one of the best
cognitive activation tasks for NIRS, and previously found that
verbal fluency is the most reliable task showing prominent and
wide-spread frontotemporal activation in normal subjects that can
be easily differentiated from that in patients with schizophrenia
[21,22]. The time needed to set up the apparatus is usually less
than 5 minutes including the audiovisual on-screen instructions,
and our version of the verbal fluency task takes less than
3 minutes, which is less demanding for the participants. Further-
more, if imaging genetics research demands a larger and wider
variety of samples in the near future, NIRS has great potential as a
neuroimaging modality to detect cortical function with ease and
speed.
Multichannel NIRS enables the noninvasive and bedside
measurement of the spatiotemporal characteristics of brain
function, which are assumed to reflect regional cerebral blood
volume. Using NIRS, typical cortical activations show not only a
deoxy-hemoglobin concentration ([deoxy-Hb]) decrease that is the
putative main source of blood-oxygenation-level-dependent
(BOLD)-contrast increase as measured by fMRI, but also a
relatively larger oxy-hemoglobin concentration ([oxy-Hb]) in-
crease. The usefulness and limitations of NIRS have been
discussed widely in previous literatures [23–26]. NIRS has been
used to assess brain function in many psychiatric disorders,
including schizophrenia, bipolar disorder, depression, dementia,
posttraumatic stress disorder, and pervasive developmental
disorders[21,22,27–30]. Considering the effect of the COMT
genotype on the response to antipsychotic drugs, if an association
is found between NIRS signals and functional polymorphisms in
the COMT gene, NIRS signals could be potentially used as a
biological marker to aid in the evaluation and prediction of
response to medication.
The purpose of this study was to use a noninvasive and less-
demanding NIRS instrument with a wide coverage of the
prefrontal cortex to investigate the association between COMT
genotype and prefrontal hemodynamic response in healthy
controls and patients with schizophrenia, and to test whether
NIRS could be a promising candidate for future translational
approach in psychiatry neuroimaging.
Methods
Participants
Participants were 45 stably maintained outpatients with chronic
schizophrenia and 60 healthy controls matched for age and
gender (Table 1). The demographic results between healthy
controls and patients with schizophrenia showed the significant
difference in education, socioeconomic status, estimated premor-
bid IQ, and task performance. Because matching for all the
factors lead to the drastic reduction in number of the subjects in
each genotype we did not match for these factors. Instead, we
gave priority to match these factors for the two genotypes in each
diagnostic group. All the participants were native Japanese
speakers and right-handed (.70) according to Oldfield’s Edin-
burgh Inventory [31].
The patients were recruited from among outpatients of the
University of Tokyo Hospital. The diagnosis of schizophrenia
was made through the Structured Clinical Interview for DSM-IV
Axis I Disorders (SCID) [32] by an experienced psychiatrist
(K.K.). For screening healthy controls, SCID non-patient edition
(SCID-NP) was used. On the same day as the NIRS experiment,
psychiatric symptoms were evaluated by one psychiatrist (K.K.)
using the Positive and Negative Syndrome Scale (PANSS) [33],
without knowledge of the NIRS data. At the time of the study,
the patients with schizophrenia were on medication with
antipsychotics and/or anxiolytics and/or antiparkinsonian
agents. Socioeconomic status (SES) was assessed using the
Hollingshead Index of social position [34]. Premorbid IQs were
estimated using the Japanese version of National Adult Reading
Test [35] (Table 1).
The exclusion criteria for both groups were neurological
illness, traumatic brain injury with any known cognitive
consequences or loss of consciousness for more than 5 minutes,
a history of electroconvulsive therapy, and alcohol/substance
abuse or addiction. An additional exclusion criterion for the
healthy control group was a history of psychiatric disease in
themselves or a family history of axis I disorder in their first-
degree relatives.
Ethics
The ethics committee of the University of Tokyo Hospital
approved this study (receipt number: 630). All the subjects gave
written informed consent in accordance with the Declaration of
Helsinki after a complete explanation of the study.
COMT and Prefrontal Function
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The cognitive activation task, which was described previously
[21,22,28], included a 30-sec pretask baseline, a 60-sec verbal
fluency task (letter version), and a 70-sec posttask baseline while
sitting on a chair. For the pre- and posttask baseline periods, the
subjects were instructed to repeat Japanese vowels (/a/, /i/, /u/,
/e/ and /o/) out loud throughout the period. This was intended to
correct the fluency task data for activation due to vocalization.
During the verbal fluency task period, they were instructed to
generate as many Japanese words beginning with a designated
syllable as possible. We modified the commonly used 60-sec verbal
fluency task in which one initial syllable is presented. In this study,
three initial syllables (first, /to/, /a/, or /na/; second, /i/, /ki/, or
/se/; third, /ta/, /o/, or /ha/) were presented in order, which
was counterbalanced among the subjects and changed every
20 sec during the 60-sec task to reduce the time during which the
subjects remained silent or gave up the task. An auditory cue
alerted the subjects to the start and end of each task and when the
syllable was changed. The total number of correct words
generated during the 60-sec activation period was defined as a
measure of task performance (Table 1).
NIRS measurement
The 52-channel NIRS machine (ETG-4000, Hitachi Medical
Co., JAPAN) measures relative changes in [oxy-Hb] and [deoxy-
Hb] using two wavelengths (695 and 830 nm) of infrared light
based on the modified Beer-Lambert law [36]. In this continuous-
wave NIRS system, these [Hb] values include a differential
pathlength factor (DPF); therefore, the unit of the NIRS
measurement is mM?mm. The distance between pairs of source-
detector probes was set at 3.0 cm and we defined each measuring
area between pairs of source-detector probes as one ‘channel’. It is
assumed that a machine, in which the source-detector spacing is
3.0 cm, measures points at 2–3 cm depth from the scalp, that is,
the surface of the cerebral cortex [37]. The probes of the NIRS
machine were fixed with thermoplastic 3611 shells, with the
lowest probes positioned along the T4-Fpz-T3 line according to
the international 10–20 system used in electroencephalography.
The 52 measurement areas are labeled ch1–ch52 from the right-
posterior to the left-anterior. This arrangement of the probes can
measure [Hb] from the bilateral prefrontal (approximately
dorsolateral [Brodmann’s area (BA) 9, 46], ventrolateral [BA 44,
45, 47], and frontopolar [BA 10]) and superior temporal cortical
surface regions. The correspondence of the probe positions and
the measurement areas on the cerebral cortex was confirmed by
superimposing the measurement positions on a magnetic reso-
nance image of a three-dimensionally reconstructed cerebral
cortex of a representative subject among the healthy controls, and
the correspondence was also supported by a multisubject study of
anatomical cranio-cerebral correction via the international 10–20
system [38,39].
The time resolution of NIRS was set at 0.1 sec. The NIRS
signal changes were analyzed using the first-order correction to
exclude task-unrelated changes during the verbal fluency task;
Because the NIRS signal was sometimes unstable at the start of the
pretask, the pretask baseline was determined as the mean across
the last 10 sec of the pretask period, and the posttask baseline was
determined as the mean across the last 5 sec of the posttask period,
and a linear fitting was performed on the basis of data between the
two baselines. The fluctuations of NIRS signals were known to be
related to such physiological activities as the systemic arterial pulse
oscillations (,1 Hz) and respiration (0.2–0.3 Hz) [24]. Thus,
Table 1. Clinical characteristics of study groups.




(N=25) Val/Val (N=20) t-test
Met carriers
(N=30) Val/Val (N=30) t-test t-test
Mean SD Mean SD p-value Mean SD Mean SD p-value p-value
Age, years 41.0 9.5 41.5 11.9 .89 37.2 12.6 37.7 13.6 .86 .12
Gender, women/men 13/12 12/8 .59
* 14/16 12/18 .60
* .22
*
Education, years 14.0 2.6 15.0 2.7 .26 16.2 3.0 16.7 2.9 .49 ,.00
Socioeconomic status (SES) 3.5 1.2 3.6 1.1 .72 1.8 0.7 1.6 0.6 .30 ,.00
Estimated premorbid IQ 99.4 12.4 101.7 13.3 .54 105.7 12.4 109.0 7.2 .22 .00
Task performance 13.7 4.3 14.8 5.9 .48 16.6 4.4 17.2 4.6 .63 .01
Age at onset, years 28.2 9.2 22.1 5.3 .09 NA NA
Duration of illness, years 12.8 7.7 17.3 12.4 .16 NA NA
PANSS
positive 15.9 5.5 15.8 4.7 .93 NA NA
negative 20.8 6.9 21.7 6.1 .40 NA NA
general psychopathology 36.5 8.6 38.2 6.4 .47 NA NA
Medication
Chlorpromazine equivalent dose, mg/day 582.5 483.5 901.4 693.5 .09 NA NA
Diazepam equivalent dose, mg/day 10.7 10.9 6.9 10.2 .24 NA NA
Biperiden equivalent dose, mg/day 3.1 2.3 4.0 2.2 .25 NA NA
Abbreviations: IQ, Intelligence Quotient; PANSS, Positive and Negative Symptom Scale; NA, not applicable.
*Chi-square test was used for testing group difference in gender distribution. Otherwise, t-test was used.
doi:10.1371/journal.pone.0005495.t001
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motion artifacts and to correct such fluctuations in the analyzed
data (moving average window: 5 sec). Grand mean waveforms
averaged across subjects were created separately for each type of
[Hb] and for each group. Because the moving average methods
cannot be used to correct all the artifacts, according to the
algorithm for quantitatively evaluating the artifacts (in supple-
mentary material of Takizawa et al. [22]), we performed a fully
automatic rejection of data with artifacts separately for each
channel, i.e., the number of averaged subjects varied across
channels (schizophrenia: N=29–45 [mean, 39.5; SD, 3.4]; healthy
subjects: N=40–60 [mean, 52.0; SD, 5.5]; percentage: schizo-
phrenia, 87.7%; healthy subjects, 86.7%, n.s.).
Genotyping
Genomic DNA was extracted from leukocytes using a standard
method. Genotyping of the COMT Val108/158Met polymor-
phism was performed using the ABI PRISM 7900HT Sequence
Detection System (Applied Biosystems, California, USA).
As shown in the results section, the sample size of the Met/Met
genotype was too small to provide sufficient statistical power to
draw a conclusion. Thus, the three genotypes in the COMT gene
were classified into two genotype subgroups according to the effect
on the catalysis of catecholamines: the genotypes with the Met
allele (we call ‘Met carriers’) versus the Val/Val genotype (we call
‘Val/Val individuals’). The Met allele genotype of the COMT
gene is associated with reduced catabolism of dopamine. The two
genotype subgroups were matched for age, gender, IQ, and task
performance in each diagnostic group (Table 1). This study was
performed in ethnically homogeneous samples (only of Japanese
descent).
Statistical methods
For data analysis using parametric statistical tests, obtained
[Hb] data from each channel were averaged across the two time
segments (pretask baseline and task period). We focused on [oxy-
Hb] here, since [oxy-Hb] increase is assumed to more directly
reflect cognitive activation than [deoxy-Hb] decrease as shown by
a stronger correlation with the BOLD signal measured by fMRI
[40] and by the results of animal studies [41], although the results
of the analysis of [deoxy-Hb] were also presented.
First, in healthy controls, to confirm the increase associated with
the verbal fluency task, the mean [Hb] for the pretask baseline
period and that for the task period were compared at each channel
using Student’s paired t-test (two-tailed). False discovery rate
(FDR) correction for multiple comparisons [52 channels] was
applied. We set the value specifying the maximum FDR to 0.05, so
that there are no more than 5% false positives on average [42].
Second, t-tests for differences in potential confounding factors,
such as age, gender, education, premorbid IQ, task performance,
clinical symptoms, and dose of medication were performed
between the two COMT genotype subgroups in healthy controls
and in patients with schizophrenia.
Third, we thought it ideal to analyze the data by repeated-
measures ANOVA with 52 channels as a within-subjects factor,
group (normal controls versus patients with schizophrenia) and
genotype (Met carriers versus Val/Val individuals) as between-
subjects factors. However, we excluded the data from the channels
that show undesirable artifacts, instead of rejecting all data of the
subject. If we used ANOVA, the data on a considerable number of
subjects should be omitted. In fact, the ANOVA permitted
including only 17 subjects (3 patients with schizophrenia and 14
healthy controls) out of original 105 (45 patients with schizophre-
nia and 60 healthy controls). Accordingly, the reduced statistical
power did not yield significant genotype-by-group interaction in
the ANOVA (F[1,13]=0.52, p=0.48). Thus, we stratified the
participants into normal controls and patients with schizophrenia,
and then performed t-tests in each channel between the two
genotypes for each group and conducted the correction for
multiple comparisons using false discovery rate (FDR).
To analyze the pattern of signal changes along the time course
with not only the amplitude but also the initial rise rate of
hemodynamic response, the first 5-sec slope and mean [Hb]
changes during the 60-sec task period between the two COMT
genotype subgroups were compared in each diagnostic group.
NIRS signal changes were compared between the two genotypes
at each channel by two-tailed Student’s t-test. P-values were
adjusted by FDR correction for multiple comparisons [p,FDR
0.05; 52 channels]. Two-tailed analysis was used because task-
load-dependent hypo- or hyperperfusions of the prefrontal cortex
in patients with schizophrenia relative to healthy controls were
reported previously [43,44]. When channels were considered
significant, we showed the effect size (cohen’s d) and 95%
confidence interval (CI). Statistical analysis was performed using
SPSS 10.1.3J software (Tokyo, Japan).
Results
Genotype determination
The genotypic distributions of the three genotypes in the
COMT genes are as follows: healthy controls, Met/Met 5 (8.3%),
Val/Met 25 (41.7%), Val/Val 30 (50.0%); patients with
schizophrenia, Met/Met 4 (8.9%), Val/Met 21(46.7%), Val/Val
20 (44.4%). The distributions of the three COMT genotypes were
not significantly different from those expected according to the
Hardy-Weinberg equilibrium in either diagnostic group.
Test for significance of [Hb] change during activation
period relative to baseline
In the healthy controls, a significant increase in [oxy-Hb]
occurred during the task period relative to the pretask baseline at
all the 52 channels (FDR corrected p; 0.0001–0.003) and a
significant decrease in [deoxy-Hb] occurred during the task period
relative to the pretask baseline at 39 channels (ch9, ch13–16,
ch18–20, ch22–52; FDR-corrected p: 0.0001–0.038); thus, the
prefrontal hemodynamic cortical activation due to the cognitive
task was confirmed. In the present NIRS study, the verbal fluency
task recruited widespread regions of the prefrontal cortical surface
area and superior temporal regions, which is in accordance with
previous studies using fMRI and PET [45,46].
Potential confounding factors
Potential confounding factors such as age, gender, education,
premorbid IQ, task performance (total number of correct words
generated), clinical symptoms, and dose of medication were not
significantly different between the two COMT genotype sub-
groups in either diagnostic group (Table 1). The first 5-sec [oxy-
Hb] slope and mean [oxy-Hb] change were not different between
women and men for either diagnostic group (two-tailed t-test:
p.FDR 0.05). In the healthy controls, the first 5-sec [oxy-Hb]
slope and mean [oxy-Hb] change were not significantly correlated
with any potential confounding factors (age, education, premorbid
IQ, task performance) at any channel (Pearson’s correlation
coefficient: p.FDR 0.05). In the patients with schizophrenia, the
5-sec [oxy-Hb] slope and mean [oxy-Hb] change were also not
significantly correlated with any potential confounding factors
(age, education, premorbid IQ, task performance, PANSS scores,
chlorpromazine equivalent dose, biperiden equivalent dose, and
COMT and Prefrontal Function
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coefficient: p.FDR 0.05). The statistical conclusions were the
same for [deoxy-Hb].
Group comparisons in [oxy-Hb] response for significant
genotype effects
First, we sought to confirm a significant difference in [oxy-Hb]
response between the two diagnostic groups as shown in previous
NIRS literature [21,22]. As predicted, the schizophrenia patients
showed a significantly lower [oxy-Hb] increase during the 60-sec
task period than the healthy controls at 50 channels (all channels
except for ch33, ch44; FDR-corrected p: 0.0001–0.048). We then
investigated the differences between the two COMT genotype
subgroups in each diagnostic group.
In the healthy controls, the first 5-sec [oxy-Hb] slope and mean
[oxy-Hb] changes during the 60-sec task periods showed no
significant difference at any channel between the Met carriers and
the Val/Val individuals (p.FDR 0.05) (Figure 1).
In the patients with schizophrenia, the [oxy-Hb] increases in the
Met carriers were significantly greater than those in the Val/Val
individuals at two channels that corresponded approximately to the
frontopolar PFC regions (ch38 (p=0.00114; d=1.07; 95%CI 0.40,
1.70; Met carriers: N=23, Val/Val individuals: N=19) and ch48
(p=0.00094; d=1.08; 95%IC 0.39, 1.72; Met carriers: N=22,
Val/Val individuals: N=18); FDR-corrected p: 0.0001–0.0019)
(Figure 2). Additionally, a few more channels that showed a trend-
level difference (uncorrected p,0.05 but not remaining significant
after FDR correction) were located approximately in the bilateral
frontopolar ([FP]), dorsolateral ([DL]) and ventrolateral ([VL])
regions (uncorrected p,0.01; [FP] ch 36 (d=0.83; 95%IC 0.19,
1.43), ch47 (d=0.93; 95%IC 0.26,1.56), [DL] ch13 (d=1.08;
95%IC 0.29, 1.80), ch18 (d=0.84; 95%IC 0.19,1.46): uncorrected
p,0.05; [FP] ch26 (d=0.63; 95% 0.01, 1.23), ch27 (d=0.73;
95%CI 0.09, 1.34), ch37 (d=0.70; 95%CI 0.04, 1.33), [DL] ch15
(d=0.85; 95%CI 20.01, 1.65), ch17 (d=1.38; 95%CI 0.20, 2.43),
ch24 (d=0.65; 95%CI 0.03, 1.25), ch28 (d=0.69; 95%CI 0.04,
1.30), ch35 (d=0.68, 95%CI 0.05, 1.29), ch39 (d=0.66; 95%CI
0.04, 1.26), [VL] ch45 (d=0.83; 95%CI 0.12, 1.50), ch50 (d=0.66;
95%CI 20.01, 1.30)) over the prefrontal cortex (Figure 3).
However, the first 5-sec [oxy-Hb] slopes were not significantly
different between the two genotype subgroups (P.FDR .05).
We also performed additional confirmatory analyses in patients
with schizophrenia, because the chlorpromazine equivalent dose
(CPZ) was not well matched (Met carriers: mean 582.5, SD 483.5;
Val/Val individuals: mean 901.4, SD 693.5; p=0.09, d=20.54,
95%IC 21.13, 0.06). First, the results of a one-way analysis of
covariance (ANCOVA) with CPZ as a covariate in the two
significant channels (ch38 and ch48) also showed a significant
main effect of the COMT genotype (ch38: F=9.49, df=1,
p=0.004; ch48: F=12.39, df=1, p=0.001). Second, using the
Figure 1. Relationship between COMT genotype and grand average waveforms in healthy controls (HC) and patients with
schizophrenia (SZ). [oxy-Hb] changes during cognitive activation are presented as grand average waveforms in 52 channels in red (Met carriers
among HC), pink (Val/Val individuals among HC), blue (Met carriers among SZ) and light-blue (Val/Val individuals among SZ) lines, respectively.
doi:10.1371/journal.pone.0005495.g001
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individuals among the patients with schizophrenia into those with
below median value (N=10; 363.66162.2 mg/day) and those
with above median value (N=10; 1439.36588.5 mg/day). The
[oxy-Hb] changes between the two subgroups of Val/Val
individuals were not different in any channel (p’s.0.2). Further-
more, the [oxy-Hb] changes in the Val/Val individuals with below
median value of CPZ were significantly lower than those in the
Met carriers ([FP] ch27: p=0.02297; ch36: p=0.02364; ch38:
p=0.00473; ch47: p=0.00151; ch48: p=0.00318; [DL] ch13:
p=0.04059; ch35: p=0.04444; [VL] ch45: p=0.01473).
Group comparisons in [deoxy-Hb] response for
significant genotype effects
The schizophrenia patients were associated with a significantly
smaller [deoxy-Hb] decrease during the 60-sec task periods than
healthy controls at 18 channels (ch18–19, ch24, ch28–29, ch31,
ch33–34, ch36–40, ch42, ch45, ch48–50; FDR-corrected p:
0.0001–0.017).
The first 5-sec slope and mean changes of [deoxy-Hb] during
the 60-sec task periods showed no significant difference at any
channel between Met carriers and Val/Val individuals in either
diagnostic group (p.FDR 0.05).
Figure 2. Relationship between COMT genotype and [oxy-Hb] change in healthy controls (HC) and patients with schizophrenia (SZ).
The mean [oxy-Hb] change in the Met carriers and the Val/Val genotype subgroups among HC and SZ are indicated in a representative channel
(Channel 38; left frontopolar PFC region). The bars show standard error of the mean.
doi:10.1371/journal.pone.0005495.g002
Figure 3. Prefrontal cortical distribution of significant effect of the COMT genotype on [oxy-Hb] changes in patients with
schizophrenia. The channels with a significant genotype difference (P#0.05) between the Met carriers and the Val/Val individuals among patients
with schizophrenia are indicated by colored areas. To illustrate the gradation in P value over the prefrontal cortical surface area, channels with FDR-
corrected P,0.0019 are colored in red, 0.0019#P,0.01 in orange, and P#0.05 in yellow. These areas approximately correspond to the bilateral
frontopolar (BA 10), dorsolateral (BA 9 and 46), and ventrolateral (BA 44 and 45) prefrontal regions.
doi:10.1371/journal.pone.0005495.g003
COMT and Prefrontal Function
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genotype subgroups
To clarify the impact of COMT genotype at great length, we
also conducted the confirmatory analysis to drop the Met/Met
subjects from the analyses (patients with schizophrenia: Val/Met:
N=21, Val/Val: N=20; Healthy controls: Val/Met: N=25,
Val/Val: N=30).
When we dropped the Met/Met subjects from the analyses,
potential confounding factors such as age, gender, education,
premorbid IQ, task performance (total number of correct words
generated), clinical symptoms, and dose of medication were also
not significantly different between the two COMT genotype
subgroups (Val/Met vs. Val/Val) in either diagnostic group. In
particular, the CPZ equivalent in the patients with schizophrenia
was not significantly different between the Val/Met genotype
subgroup (594.16464.2 mg/day) and the Val/Val genotype
subgroup (901.46693.5 mg/day) (p=0.11, n.s.).
In the healthy controls, the first 5-sec [oxy-Hb] slope and mean
[oxy-Hb] changes during the 60-sec task periods showed no
significant difference at any channel between the Val/Met and
Val/Val individuals (p.FDR 0.05).
In the patients with schizophrenia, the first 5-sec [oxy-Hb] slope
and mean [oxy-Hb] changes during the 60-sec task periods also
showed no significant difference at any channel between the Val/
Met and Val/Val individuals (p.FDR 0.05). However, in a
similar manner with the difference of mean [oxy-Hb] change
between the Met carriers and Val/Val genotype subgroups, a few
channels that showed a trend-level difference (uncorrected p,0.05
but not remaining significant after FDR correction) were located
approximately in the bilateral frontopolar ([FP]), dorsolateral
([DL]) and ventrolateral ([VL]) regions. (uncorrected p,0.01; [FP]
ch27 (p=0.0019), ch38 (p=0.0020), ch48 (p=0.0017), [DL]:ch11
(p=0.0085); ch13 (p=0.0081); ch18 (p=0.0095): uncorrected
p,0.05; [FP]: ch26 (p=0.0457), ch36 (p=0.0126), ch47
(p=0.0103), [DL]: ch3 (p=0.0138), ch8 (p=0.0241), ch10
(0.0271), ch24 (p=0.0184), ch28 (p=0.0271), [VL]: ch 32
(p=0.0315), ch35 (p=0.0261), ch45 (p=0.0260) over the PFC.
The first 5-sec slope and mean changes of [deoxy-Hb] during
the 60-sec task periods showed no significant difference at any
channel between Met carriers and Val/Val individuals in either
diagnostic group (p.FDR 0.05).
Discussion
Using a 52-channel NIRS with a wide coverage over the
prefrontal cortical surface area, we showed that the prefrontal
hemodynamic response during a verbal fluency task was
significantly associated with COMT genotype in patients with
schizophrenia, but not in healthy controls. The increase in [oxy-
Hb] in the COMT Met carriers during the verbal fluency task was
significantly greater than that of COMT Val/Val individuals in
the PFC of patients with schizophrenia, but these differences were
not found to be significant in healthy controls. In this COMT
genotype comparison, potential confounding factors such as age,
gender, education, premorbid IQ, task performance, clinical
symptoms, and dose of medication were matched between the two
genotype subgroups in both diagnostic groups, and therefore were
not likely to account for the effect of the COMT genotype on the
prefrontal hemodynamic response of patients with schizophrenia.
Furthermore, the use of the 52-channel NIRS in this study
revealed that the significant association between the COMT
genotype and prefrontal hemodynamic activation in patients with
schizophrenia was most profound in the frontopolar PFC (BA10;
also known as anterior or rostral PFC) and had a gradation over
the prefrontal cortical area tapering from the frontopolar PFC to
the more lateral PFC (dorsolateral and ventrolateral PFC)
(Figure 3).
To our knowledge, this is the first NIRS report that implicated
the impact of COMT genotype on prefrontal cortical function in
schizophrenia. These data, consistent with findings from previous
fMRI, ERP (P50, P300), PET and neuropsychological studies
[7,47–53], suggest that the COMT Met allele may have a
beneficial effect on prefrontal function in schizophrenia. These
results lead to the suggestion that prefrontal activity assessed by
NIRS may offer promise as a noninvasive clinical tool for
evaluating the spatiotemporal characteristics of prefrontal function
in schizophrenia.
No effect of COMT genotype in healthy controls
Dopamine plays a critical role in modulating normal PFC
function, and the modulation of dopamine levels via catabolism by
COMT is considered to be important in the PFC, relative to the
striatum, because it was reported that the expression of dopamine
transporters in the PFC is less than that in the striatum [54]. As the
Val allele facilitates dopamine metabolism, dopamine in the PFC
of the individuals with the COMT Val genotype is less than that
with the Met genotype, which leads to functional attenuation of
the dopaminergic nervous system in individuals with the COMT
Val genotype. Therefore, we need to discuss why we did not find a
significant association between the COMT genotype and
prefrontal function in healthy controls, which is similar to the
results of a previous imaging genetics study on the COMT
genotype in a Japanese population [55]. One possibility would be
that healthy controls with the COMT Val/Val genotype might
have other factors to compensate for the attenuation of the
dopamine level via catabolism by COMT in the PFC, because the
dopaminergic nervous system and PFC function might be
modulated by not only COMT SNP variation. Considering the
hypothesis on the inverted-U-shaped relationship between dopa-
mine levels and PFC function [16,56], it might be that healthy
controls regardless of Met/Val polymorphism in the COMT
genotype are almost all situated in the vicinity of the optimum level
on the inverted-U curve of the prefrontal cortical function
(Figure 4). Furthermore, three channels that showed a trend-level
difference (uncorrected p,0.05 but not remaining significant after
FDR correction) were located approximately in the left dorsolat-
eral ([DL]) and bilateral ventrolateral ([VL]) regions ([DL]: ch 30
(d=20.55; 95%IC 21.17, 0.10) [VL]: ch22 (d=20.52: 95%IC
21.08, 0.06), ch 41 (d=20.91; 95%IC 21.48, 20.30)), which
showed that the prefrontal hemodynamic response of the Val/Val
individuals was greater than that of the Met carriers among the
healthy controls. These inverse slight COMT genotype effects
(with nonsignificance but more than medium effect size) in normal
controls suggested the possibility that individuals with the Met
allele might have dopamine levels that are not necessarily more
functionally optimal than those of the Val/Val individuals under
normal conditions. In contrast, the inverted-U curve may be
shifted in schizophrenia, possibly resulting in a larger effect of the
COMT genotype on the prefrontal cortical function as measured
by NIRS (Figure 4).
Effect of COMT genotype on prefrontal subregions
In previous fMRI and PET studies that employed the n-back
task [7,49,53], a significant effect of the COMT genotype in
patients with schizophrenia was reported in the dorsolateral and
ventrolateral PFC. In this study, the prominent impact of the
COMT in patients with schizophrenia was found in the
frontopolar PFC, whereas there was also a significant trend
COMT and Prefrontal Function
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Possible explanations for this discrepancy may be as follows. First,
there might be a task-related difference in prefrontal cortical
activation between verbal fluency and n-back. The verbal fluency
task not only concurrently requires working memory capacity to
hold the already-generated words but also requires retrieval of
items from long-term memory storage and inhibition of inappro-
priate response [57]. Thus, the verbal fluency task might recruit
broader regions including the frontopolar prefrontal cortical area
than n-back, which requires a more simple working memory
capacity [45].
Second, consistent with previous neuroimaging studies, larger
[oxy-Hb] increase and concurrent large [deoxy-Hb] decrease
during the verbal fluency task were detected in the dorsolateral
and ventrolateral PFC using NIRS [21,22,28]. In contrast,
however, the frontopolar hemodynamic response showing large
[oxy-Hb] increase but slight [deoxy-Hb] decrease may be an
activation pattern that is relatively difficult to detect using BOLD-
contrast fMRI, because the decrease in paramagnetic [deoxy-Hb]
is the primary source of BOLD-contrast increases (Table 2).
Furthermore, because the frontopolar cortex is located in the
vicinity of air-filled spaces of the nasal cavity, the corresponding
magnetic susceptibility differences at the air–tissue or bone–tissue
interface result in severe distortions and regional signal losses in
long-TE gradient-echo images, particularly for ultrafast imaging
techniques such as echo-planar imaging at a high magnetic field.
Also, several studies of NIRS and fMRI measurements with the
same individuals undergoing the same task suggested that the two
signals were in good agreement [58]. Thus, the ability to observe
both [oxy-Hb] and [deoxy-Hb] change in the frontopolar region
may be an advantageous feature of NIRS.
Third, the frontopolar PFC (BA10) has evolved to become large
and specialized to play a role in high-order integrative prefrontal
function, which integrates the outcomes of two or more separate
cognitive operations involving dorsolateral and ventrolateral PFC
functions in the pursuit of a higher behavioral goal [59,60].
Interestingly, the Met allele of the COMT genotype appears to be
unique to humans, because it has not been found in nonhuman
primates [61]. The evolutionary implications in association with
high-order cognitive function in human hierarchical PFC might
explain the prominent genotype effect found in the frontopolar
PFC (BA10) [60]. In this study, the reduced NIRS signal changes
in patients with schizophrenia were found to be significant in a
wide area of the PFC relative to healthy controls, and patients with
schizophrenia with the COMT Val/Val genotype had signifi-
cantly more reduced NIRS signal changes than the Met carriers in
the frontopolar PFC. These suggest that the COMT Met allele
might be one of the influential factors in the evolution of the
human hierarchical PFC and one of the protective factors in the
development of prefrontal cognitive dysfunction in schizophrenia.
Effect of COMT genotype on neuroimaging signals
The overactivation response in fMRI BOLD signals and PET
cerebral blood flow data in the Val/Val genotypes relative to the
Met/Met genotypes (hyperfrontality) have been reported and
explained as inefficient prefrontal function in patients with
schizophrenia [7,49,53,62]. On the other hand, because the
current study as well as previous NIRS studies with the verbal
fluency task have found underactivation of NIRS signals
(hypofrontality) in schizophrenia patients relative to healthy
controls [21,22], it would be appropriate to interpret the
attenuation of NIRS signals during the verbal fluency task as the
deterioration of PFC function. Therefore, it is reasonable that the
Met carriers with schizophrenia had larger prefrontal activity as
measured by NIRS than that in the Val/Val individuals in the
current study. Nevertheless, owing to the diminished regulatory
effects of dopamine and reduced cortical signal-to-noise ratio [63],
it has been speculated that patients with schizophrenia and the Val
allele may be predisposed to dysregulation of local gamma-
aminobutyric acid (GABA) and glutamate transmission in the PFC
[64], which might lead to the suggestion that either ‘hyperfron-
tality’ or ‘hypofrontality’ may be associated with prefrontal
abnormality in patients with schizophrenia [62]. In this study,
both healthy controls and schizophrenia patients with Val/Val
genotype had wider standard error bars (Figure 2), possibly
because of the diminished regulatory effects of dopamine and
reduced cortical signal-to-noise ratio [63,64].
Potential application to clinical evaluation and
translational approach
We have also attempted to examine the clinical usefulness of this
noninvasive neuroimaging technique. Multichannel NIRS enables
the noninvasive and less-demanding measurement of the spatio-
temporal characteristics of brain cortical function, which was able
to detect the impact of COMT variation in the PFC in this study.
Previous studies [19,20,65] showed that the COMT Met genotype
is associated with greater improvement of memory performance
and negative symptoms in patients with schizophrenia treated with
antipsychotic drugs. In the present study, the antipsychotic
medication dose of Val/Val individual was not significantly higher
than that of Met carriers (p=0.09) or Val/Met individuals
(p=0.11). However, the present findings leave the possibility that
patients with the COMT Met genotype respond more favorably to
antipsychotic treatment and that Val /Val individuals require a
higher medication dose for being clinically stable. Beltolino et al
[19] suggested increasing prefrontal levels of dopamine induced by
antipsychotics might have a greater impact in Met/Met
individuals, possibly because the effect lasts longer or crosses a
Figure 4. The hypothetical diagram of the inverted-U shaped
relationship between dopamine availability and prefrontal
cortical function.
doi:10.1371/journal.pone.0005495.g004
Table 2. Pattern diagram of NIRS signal activations by PFC
regions.
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positively modulates intrinsic prefrontal processing. Taken togeth-
er, prefrontal hemodynamic response assessed by NIRS could help
to predict such effects before starting the treatment and might be
useful for the evaluation and prediction of medicinal benefits.
Therefore, this study not only replicated the association between
COMT genotype and prefrontal function in previous studies, but
also showed the usefulness of NIRS in future research using
translational approaches.
Imaging genetics studies have shown that brain function by
neuroimaging as an intermediate phenotype could be a more
sensitive tool to understand how neurobiology bridges the gap
from genes to behavior and psychiatric symptoms than the gene
itself as shown by association studies [66]. Although the possibility
of false positive findings has been a concern when genetic variants
(SNPs) of uncertain functional relevance are related to imaging
data in imaging genetics study, Meyer-Lindenberg et al. [67]
provided the empirical data on false positive rates that the type I
error was well controlled in imaging genetics and indicated that
positive neuroimaging findings in imaging genetics paradigms
point toward positive neurofunctional effects that merit further
study using translational approaches. Further extensive longitudi-
nal study using translational approaches will be required in the
near future to investigate the relationship between the NIRS
signals and the improvement of clinical characteristics with
antipsychotic medication. Fortunately, NIRS measurements have
several beneficial features, being noninvasive, portable, low in
running cost, less restraining and less demanding for the
participants compared with other imaging methods. These
characteristics make NIRS highly desirable for application to
repeated clinical evaluations of individual patients.
Limitations
Some limitations of this study should be pointed out. First,
because the 45 participants with schizophrenia were all medicated
(Met carriers, only first-generation antipsychotic drugs: 13
patients, only second-generation antipsychotic drugs: 4 patients,
both drugs: 8 patients; Val/Val individuals, only first-generation
antipsychotic drugs: 8 patients, only second-generation antipsy-
chotic drugs: 5 patients, both drugs: 7 patients; chi-square test,
df=2, p=0.66, n.p.), we cannot fully exclude the possibility of
medication effects, although there was no significant correlation
between dose of medication (chlorpromazine equivalent dose,
biperiden equivalent dose, and diazepam equivalent dose) and
hemodynamic response at any channel. Investigations into drug-
naive or drug-free patients are an important next step. Second, the
demographic results between normal controls and patients with
schizophrenia showed the significant difference in education, socio-
economic status, estimated premorbid IQ, and task performance.
As described in Methods section, we gave priority to match these
factors for the two genotypes in each diagnostic group and we did
not match for these factors between normal controls and patients
with schizophrenia, because matching for all the factors lead to the
drasticreductioninnumberofthesubjectsineachgenotype.Infact,
these factors were not significantly correlated with NIRS signals at
any channel in either group. However, imaging genetic studies in
demographically matched samples between normal controls and
patients with schizophrenia are also ideal. Third, the results of
functional MRI and PET studies during n-back task differed from
those of this NIRS study regarding prefrontal regions and signal
direction of the impact of the COMT genotype. For an extensive
investigation, a replication study using the n-back task with NIRS is
required. Fourth, some researchers placed a high value on [deoxy-
Hb] decrease due to cognitive activation [25]. However, variances
in [deoxy-Hb] were too small to detect the impact of the COMT
genotype in patients with schizophrenia in this study. A different
prefrontal task with larger effects on [deoxy-Hb] should be
employed to further study the effect of the COMT genotype on
prefrontal function.
Conclusions
In conclusion, an implication of the impact of the COMT
genotype on prefrontal cortical function in patients with
schizophrenia was also identified by noninvasive and less-
demanding NIRS measurement. The evidence of association
between COMT genotype and increasing risk for developing
schizophrenia remains to be elucidated; however, the results of this
study suggested that NIRS that is sensitive to COMT genetic
variation in patients with schizophrenia might be a noninvasive
tool and that prefrontal hemodynamic response may be a useful
index for the evaluation and prediction of clinical response such as
improvement of prefrontal cognitive dysfunction by atypical
antipsychotic medication in clinical settings. This study not only
replicated the effect of COMT on prefrontal cognitive function in
schizophrenia, but also showed the usefulness of NIRS in future
translational research on psychiatric neuroimaging.
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